Ally Bridge Group

Kandu is a tech-enabled healthcare company focused on enhancing the quality of life for stroke survivors and their families. The company specializes in stroke recovery training, stroke detection research, and educational services. It provides remote clinical support through a dedicated app, delivering personalized information, resources, and guidance tailored to the needs of each user. This approach empowers stroke survivors to take control of their recovery and adjust to life after a stroke.

Cardiac Dimensions, Inc. is a medical device company focused on developing minimally invasive treatments for heart failure and associated cardiovascular conditions. The company is known for its Carillon Mitral Contour System, a permanent implant designed to treat functional mitral regurgitation through a non-surgical, catheter-based approach that reshapes the mitral valve and reduces regurgitation. Established in 2000, Cardiac Dimensions is headquartered in Kirkland, Washington, with additional operations in Sydney, Australia, and Offenbach, Germany.

Aadi Bioscience, Inc. is a clinical-stage biopharmaceutical company based in Pacific Palisades, California, focused on developing precision therapies for genetically-defined cancers. The company specializes in mTOR inhibitors, particularly ABI-009, aimed at treating patients with alterations in the TSC1 or TSC2 genes, where existing mTOR inhibitors have limitations in pharmacology, drug delivery, or safety. Aadi's primary focus is on providing transformational therapies for patients with ultra-rare cancers, such as perivascular epithelioid cell tumors (PEComa). Since its founding in 2011, Aadi Bioscience has aimed to address significant unmet medical needs in oncology and related therapeutic areas.

Aadi Bioscience, Inc. is a clinical-stage biopharmaceutical company based in Pacific Palisades, California, focused on developing precision therapies for genetically-defined cancers. The company specializes in mTOR inhibitors, particularly ABI-009, aimed at treating patients with alterations in the TSC1 or TSC2 genes, where existing mTOR inhibitors have limitations in pharmacology, drug delivery, or safety. Aadi's primary focus is on providing transformational therapies for patients with ultra-rare cancers, such as perivascular epithelioid cell tumors (PEComa). Since its founding in 2011, Aadi Bioscience has aimed to address significant unmet medical needs in oncology and related therapeutic areas.

Vida Health, Inc. is a virtual care company based in San Francisco, California, focused on addressing chronic physical and behavioral health conditions. The company offers a comprehensive digital platform that combines artificial intelligence with human support, providing users access to coaches, nutritionists, diabetes educators, nurses, trainers, and licensed therapists. This platform features personalized content, lessons, and habit recommendations, along with video sessions and messaging to facilitate communication. Vida Health's approach aims to treat the whole health of individuals by integrating mental and physical care, helping users prevent, manage, and potentially reverse chronic conditions such as diabetes and hypertension, as well as associated mental health issues like stress, depression, and anxiety. Founded in 2014, Vida Health has earned the trust of major employers and health plans in the United States for its clinically validated services.

ProMIS Neurosciences is a development-stage biotech company that discovers and develops precision therapeutics and companion diagnostics for early detection and effective treatment of neurodegenerative diseases, in particular, Alzheimer’s disease (AD) and amyotrophic lateral sclerosis (ALS). It was founded in 2004 and headquartered in Toronto, Canada.

Imperative Care focuses on developing a portfolio of innovative solutions to address the vast and urgent unmet needs in stroke care. It focuses on medical technology designed to expedite and improve the effectiveness of treatment, giving patients a chance for optimal recovery.

Imperative Care focuses on developing a portfolio of innovative solutions to address the vast and urgent unmet needs in stroke care. It focuses on medical technology designed to expedite and improve the effectiveness of treatment, giving patients a chance for optimal recovery.